Trial Profile
A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 06 Sep 2022 Status changed from active, no longer recruiting to completed.
- 10 Feb 2022 Planned End Date changed from 24 Mar 2022 to 27 Jul 2022.
- 10 Feb 2022 Planned primary completion date changed from 24 Mar 2022 to 27 Jul 2022.